A New Debate Over Weight-Loss Injections

A new analysis of real-world data has suggested that GLP-1 receptor agonists may slightly increase the risk of erectile dysfunction (problems with erections) in men with type 2 diabetes. In the study, which used US electronic health records, the rate of ED diagnosis over about three years of follow-up was 26% higher in men using GLP-1 drugs than in those using certain other diabetes medications.

However, it is emphasized that the results are not conclusive and should be interpreted with caution. The fact that the association lost significance in sensitivity analyses suggests that unmeasured factors or selection bias may have played a role. In addition, some previous studies have suggested that GLP-1 drugs may have positive effects on erectile function through weight loss, improved blood vessel function, and metabolic improvement.

The researchers note that erectile dysfunction is already very common in men with diabetes and involves a complex mechanism related to endothelial dysfunction, neuropathy, and nitric oxide disorders. This makes it difficult to isolate the direct effect of GLP-1 drugs.

In conclusion, the link between GLP-1 agonists and erectile dysfunction remains controversial!

Source

Tang, H., et al. (2026). GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.103857